PDMR/Director Shareholding, Issue of Equity & TVR

Kromek Group PLC

01 June 2026

 

1 June 2026

Kromek Group plc 

("Kromek", the "Company" or the "Group") 

PDMR/Director Shareholding, Issue of Equity and Total Voting Rights

Kromek (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, announces that it has issued and allotted a total of 163,071 ordinary shares of 1p each in the Company ("Ordinary Shares") to satisfy the exercise of options by employees of the Company. This includes the exercise of 150,000 options by Berry Beumer, an Executive Director of the Company, on 28 May 2026. Following this exercise, Mr. Beumer has an interest in 230,000 Ordinary Shares, representing 0.03% of the Company's enlarged issued share capital.

Total voting rights

Application has been made to the London Stock Exchange for the 163,071 Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective at 8 a.m. on or around 4 June 2026. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in the Company.

Following Admission, the total number of Ordinary Shares in issue will be 655,299,911. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries 

Kromek Group plc
Arnab Basu, CEO  Claire Burgess, CFO	[phone]
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance  Andrew Burdis - ECM Michael Johnson - Sales	[phone]
Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury	[phone]

Kromek Group plc 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

 In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.  

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Berry Beumer
2	Reason for the notification
a)	Position/status	Chief Operating Officer and President of the Advanced Imaging Division
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Kromek Group plc
b)	LEI	213800VLHYXGHEX5VQ48
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Options over ordinary shares of 1 penny each
	Identification code	GB00BD7V5D43
b)	Nature of the transaction	Exercise of options
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			1p	150,000
d)	Aggregated information -      Aggregated volume -      Price	N/A
e)	Date of the transaction	28 May 2026
f)	Place of the transaction	Outside a trading venue

 

END